Annual CFF
$37.06 M
-$6.12 M-14.17%
December 31, 2023
Summary
- As of February 12, 2025, ABEO annual cash flow from financing activities is $37.06 million, with the most recent change of -$6.12 million (-14.17%) on December 31, 2023.
- During the last 3 years, ABEO annual CFF has risen by +$35.12 million (+1814.10%).
- ABEO annual CFF is now -67.47% below its all-time high of $113.90 million, reached on December 31, 2019.
Performance
ABEO Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$299.00 K
-$73.98 M-100.41%
September 30, 2024
Summary
- As of February 12, 2025, ABEO quarterly cash flow from financing activities is -$299.00 thousand, with the most recent change of -$73.98 million (-100.41%) on September 30, 2024.
- Over the past year, ABEO quarterly CFF has dropped by -$7.77 million (-104.00%).
- ABEO quarterly CFF is now -100.31% below its all-time high of $96.53 million, reached on December 31, 2019.
Performance
ABEO Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$106.29 M
-$23.27 M-17.96%
September 30, 2024
Summary
- As of February 12, 2025, ABEO TTM cash flow from financing activities is $106.29 million, with the most recent change of -$23.27 million (-17.96%) on September 30, 2024.
- Over the past year, ABEO TTM CFF has increased by +$69.23 million (+186.83%).
- ABEO TTM CFF is now -17.96% below its all-time high of $129.57 million, reached on June 30, 2024.
Performance
ABEO TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ABEO Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -14.2% | -104.0% | +186.8% |
3 y3 years | +1814.1% | -272.8% | +1145.7% |
5 y5 years | +576.6% | -106.9% | -6.7% |
ABEO Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -14.2% | +49.1% | -100.4% | +92.1% | -18.0% | +735.5% |
5 y | 5-year | -67.5% | +1814.1% | -100.3% | +92.1% | -18.0% | +5390.3% |
alltime | all time | -67.5% | +1063.8% | -100.3% | +95.5% | -18.0% | +2864.4% |
Abeona Therapeutics Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$299.00 K(-100.4%) | $106.29 M(-18.0%) |
Jun 2024 | - | $73.68 M(+189.6%) | $129.57 M(+107.3%) |
Mar 2024 | - | $25.44 M(+240.7%) | $62.50 M(+68.7%) |
Dec 2023 | $37.06 M(-14.2%) | $7.47 M(-67.5%) | $37.06 M(-48.8%) |
Sep 2023 | - | $22.98 M(+247.2%) | $72.36 M(+35.1%) |
Jun 2023 | - | $6.62 M(<-9900.0%) | $53.57 M(+24.1%) |
Mar 2023 | - | -$4000.00(-100.0%) | $43.17 M(-0.0%) |
Dec 2022 | $43.17 M(+73.7%) | $42.77 M(+920.9%) | $43.17 M(+157.9%) |
Sep 2022 | - | $4.19 M(-210.8%) | $16.74 M(+31.6%) |
Jun 2022 | - | -$3.78 M(<-9900.0%) | $12.72 M(-33.0%) |
Mar 2022 | - | $0.00(-100.0%) | $18.98 M(-23.6%) |
Dec 2021 | $24.86 M(+1184.1%) | $16.33 M(+9339.9%) | $24.86 M(+191.4%) |
Sep 2021 | - | $173.00 K(-93.0%) | $8.53 M(+2.1%) |
Jun 2021 | - | $2.48 M(-57.8%) | $8.36 M(+7.0%) |
Mar 2021 | - | $5.88 M(>+9900.0%) | $7.81 M(+303.6%) |
Dec 2020 | $1.94 M(-98.3%) | $3000.00(>+9900.0%) | $1.94 M(-98.0%) |
Sep 2020 | - | $0.00(-100.0%) | $98.46 M(-4.2%) |
Jun 2020 | - | $1.93 M(>+9900.0%) | $102.80 M(-9.7%) |
Mar 2020 | - | $0.00(-100.0%) | $113.87 M(-0.0%) |
Dec 2019 | $113.90 M(+1979.6%) | $96.53 M(+2124.1%) | $113.90 M(+555.6%) |
Sep 2019 | - | $4.34 M(-66.6%) | $17.37 M(+7.8%) |
Jun 2019 | - | $13.01 M(>+9900.0%) | $16.11 M(+338.3%) |
Mar 2019 | - | $28.00 K(-2900.0%) | $3.68 M(-32.9%) |
Dec 2018 | $5.48 M(-94.1%) | -$1000.00(-100.0%) | $5.48 M(-94.1%) |
Sep 2018 | - | $3.08 M(+440.2%) | $92.74 M(-2.1%) |
Jun 2018 | - | $570.00 K(-68.8%) | $94.72 M(+0.5%) |
Mar 2018 | - | $1.83 M(-97.9%) | $94.23 M(+2.0%) |
Dec 2017 | $92.40 M(+117.2%) | $87.26 M(+1624.5%) | $92.40 M(+98.7%) |
Sep 2017 | - | $5.06 M(+5923.8%) | $46.51 M(+9.5%) |
Jun 2017 | - | $84.00 K(+8300.0%) | $42.47 M(-0.2%) |
Mar 2017 | - | $1000.00(-100.0%) | $42.54 M(+0.0%) |
Dec 2016 | $42.54 M(+19.3%) | $41.37 M(+3959.7%) | $42.54 M(+3538.8%) |
Sep 2016 | - | $1.02 M(+579.3%) | $1.17 M(-92.5%) |
Jun 2016 | - | $150.00 K(>+9900.0%) | $15.56 M(-56.8%) |
Mar 2016 | - | $0.00(0.0%) | $36.05 M(+1.1%) |
Dec 2015 | $35.65 M(+180.6%) | $0.00(-100.0%) | $35.65 M(-25.9%) |
Sep 2015 | - | $15.41 M(-25.3%) | $48.11 M(+46.0%) |
Jun 2015 | - | $20.64 M(-5260.3%) | $32.95 M(+167.7%) |
Mar 2015 | - | -$400.00 K(-103.2%) | $12.31 M(-3.1%) |
Dec 2014 | $12.71 M(>+9900.0%) | $12.46 M(+4882.8%) | $12.71 M(+4982.8%) |
Sep 2014 | - | $250.00 K(>+9900.0%) | $250.00 K(+1288.9%) |
Jun 2014 | - | $0.00(0.0%) | $18.00 K(-37.9%) |
Mar 2014 | - | $0.00(0.0%) | $29.00 K(0.0%) |
Dec 2013 | $29.00 K(-98.5%) | $0.00(-100.0%) | $29.00 K(-98.5%) |
Sep 2013 | - | $18.00 K(+63.6%) | $1.93 M(+0.9%) |
Jun 2013 | - | $11.00 K(-99.4%) | $1.92 M(+0.6%) |
Dec 2012 | $1.90 M(-38.1%) | $1.90 M(>+9900.0%) | $1.90 M(-38.1%) |
Sep 2012 | - | $0.00(0.0%) | $3.08 M(0.0%) |
Jun 2012 | - | $0.00(-100.0%) | $3.08 M(0.0%) |
Dec 2011 | $3.08 M | $3.08 M(>+9900.0%) | $3.08 M(-57.6%) |
Sep 2011 | - | $0.00(0.0%) | $7.25 M(-0.7%) |
Jun 2011 | - | $0.00(0.0%) | $7.30 M(-1.7%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2011 | - | $0.00(-100.0%) | $7.43 M(-44.1%) |
Dec 2010 | $13.29 M(+7326.3%) | $7.25 M(>+9900.0%) | $13.29 M(+119.3%) |
Sep 2010 | - | $52.00 K(-58.7%) | $6.06 M(-1.5%) |
Jun 2010 | - | $126.00 K(-97.9%) | $6.15 M(+1.9%) |
Mar 2010 | - | $5.86 M(>+9900.0%) | $6.04 M(+3274.9%) |
Dec 2009 | $179.00 K(-91.9%) | $21.00 K(-85.4%) | $179.00 K(-367.2%) |
Sep 2009 | - | $144.00 K(+928.6%) | -$67.00 K(-58.4%) |
Jun 2009 | - | $14.00 K(>+9900.0%) | -$161.00 K(+0.6%) |
Mar 2009 | - | $0.00(-100.0%) | -$160.00 K(-107.2%) |
Dec 2008 | $2.22 M(-69.9%) | -$225.00 K(-550.0%) | $2.22 M(-77.3%) |
Sep 2008 | - | $50.00 K(+233.3%) | $9.79 M(+0.3%) |
Jun 2008 | - | $15.00 K(-99.4%) | $9.76 M(-0.0%) |
Mar 2008 | - | $2.38 M(-67.6%) | $9.76 M(+32.2%) |
Dec 2007 | $7.38 M(+38.6%) | $7.34 M(>+9900.0%) | $7.38 M(+689.3%) |
Sep 2007 | - | $16.00 K(-15.8%) | $935.00 K(+6.1%) |
Jun 2007 | - | $19.00 K(>+9900.0%) | $881.00 K(+6.0%) |
Mar 2007 | - | $0.00(-100.0%) | $831.00 K(-84.4%) |
Dec 2006 | $5.33 M(-238.5%) | $900.00 K(-2468.4%) | $5.33 M(-334.0%) |
Sep 2006 | - | -$38.00 K(+22.6%) | -$2.28 M(+30.3%) |
Jun 2006 | - | -$31.00 K(-100.7%) | -$1.75 M(-0.7%) |
Mar 2006 | - | $4.50 M(-167.1%) | -$1.76 M(-54.2%) |
Dec 2005 | -$3.85 M(-142.8%) | -$6.70 M(-1465.0%) | -$3.85 M(-233.2%) |
Sep 2005 | - | $491.00 K(-1215.9%) | $2.89 M(+16.7%) |
Jun 2005 | - | -$44.00 K(-101.8%) | $2.47 M(-4.4%) |
Mar 2005 | - | $2.41 M(+8210.3%) | $2.59 M(-71.2%) |
Dec 2004 | $8.99 M(-1835.3%) | $29.00 K(-63.3%) | $8.99 M(+0.4%) |
Sep 2004 | - | $79.00 K(+11.3%) | $8.95 M(+0.7%) |
Jun 2004 | - | $71.00 K(-99.2%) | $8.89 M(+1.6%) |
Mar 2004 | - | $8.81 M(<-9900.0%) | $8.75 M(-1788.8%) |
Dec 2003 | -$518.00 K(+590.7%) | -$7000.00(-141.2%) | -$518.00 K(-3.7%) |
Sep 2003 | - | $17.00 K(-123.6%) | -$538.00 K(-7.6%) |
Jun 2003 | - | -$72.00 K(-84.2%) | -$582.00 K(+8.6%) |
Mar 2003 | - | -$456.00 K(+1588.9%) | -$536.00 K(+614.7%) |
Dec 2002 | -$75.00 K(-112.3%) | -$27.00 K(0.0%) | -$75.00 K(+5.6%) |
Sep 2002 | - | -$27.00 K(+3.8%) | -$71.00 K(-112.5%) |
Jun 2002 | - | -$26.00 K(-620.0%) | $569.00 K(-4.8%) |
Mar 2002 | - | $5000.00(-121.7%) | $598.00 K(-1.6%) |
Dec 2001 | $608.00 K(-97.9%) | -$23.00 K(-103.8%) | $608.00 K(-13.4%) |
Sep 2001 | - | $613.00 K(>+9900.0%) | $702.00 K(-95.0%) |
Jun 2001 | - | $3000.00(-80.0%) | $14.01 M(-2.6%) |
Mar 2001 | - | $15.00 K(-78.9%) | $14.38 M(-51.0%) |
Dec 2000 | $29.34 M(+973.3%) | $71.00 K(-99.5%) | $29.34 M(-0.2%) |
Sep 2000 | - | $13.92 M(+3641.1%) | $29.41 M(+62.6%) |
Jun 2000 | - | $372.00 K(-97.5%) | $18.09 M(+2.1%) |
Mar 2000 | - | $14.98 M(>+9900.0%) | $17.72 M(+548.0%) |
Dec 1999 | $2.73 M(-37.9%) | $134.00 K(-94.8%) | $2.73 M(+5.2%) |
Sep 1999 | - | $2.60 M(>+9900.0%) | $2.60 M(>+9900.0%) |
Jun 1999 | - | $0.00(0.0%) | $0.00(0.0%) |
Mar 1999 | - | $0.00 | $0.00 |
Dec 1998 | $4.40 M(-2571.9%) | - | - |
Dec 1997 | -$178.00 K(-102.5%) | - | - |
Dec 1996 | $7.10 M(-6865.7%) | - | - |
Dec 1995 | -$105.00 K | - | - |
FAQ
- What is Abeona Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Abeona Therapeutics?
- What is Abeona Therapeutics annual CFF year-on-year change?
- What is Abeona Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Abeona Therapeutics?
- What is Abeona Therapeutics quarterly CFF year-on-year change?
- What is Abeona Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Abeona Therapeutics?
- What is Abeona Therapeutics TTM CFF year-on-year change?
What is Abeona Therapeutics annual cash flow from financing activities?
The current annual CFF of ABEO is $37.06 M
What is the all time high annual CFF for Abeona Therapeutics?
Abeona Therapeutics all-time high annual cash flow from financing activities is $113.90 M
What is Abeona Therapeutics annual CFF year-on-year change?
Over the past year, ABEO annual cash flow from financing activities has changed by -$6.12 M (-14.17%)
What is Abeona Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of ABEO is -$299.00 K
What is the all time high quarterly CFF for Abeona Therapeutics?
Abeona Therapeutics all-time high quarterly cash flow from financing activities is $96.53 M
What is Abeona Therapeutics quarterly CFF year-on-year change?
Over the past year, ABEO quarterly cash flow from financing activities has changed by -$7.77 M (-104.00%)
What is Abeona Therapeutics TTM cash flow from financing activities?
The current TTM CFF of ABEO is $106.29 M
What is the all time high TTM CFF for Abeona Therapeutics?
Abeona Therapeutics all-time high TTM cash flow from financing activities is $129.57 M
What is Abeona Therapeutics TTM CFF year-on-year change?
Over the past year, ABEO TTM cash flow from financing activities has changed by +$69.23 M (+186.83%)